This Article Full Text Full Text (PDF) All Versions of this Article: 1940-6207.CAPR-09-0063v1 2/6/538    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Amin, A.R.M. R. Articles by Shin, D. M. PubMed PubMed Citation Articles by Amin, A.R.M. R. Articles by Shin, D. M. Related Collections Preclinical Intervention Preclinical Intervention: In Vitro: Drugs, Mechanisms

Synergistic Growth Inhibition of Squamous Cell Carcinoma of the Head and Neck by Erlotinib and Epigallocatechin-3-Gallate: The Role of p53-Dependent Inhibition of Nuclear Factor-B

Authors' Affiliation: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia

Requests for reprints: Dong M. Shin, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322. Phone: 404-778-2980; Fax: 404-778-5520; E-mail: dmshin{at}emory.edu.

We have previously reported that the green tea polyphenol epigallocatechin-3-gallate (EGCG) and the epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib had synergistic growth-inhibitory effects in cell culture and a nude mouse xenograft model of squamous cell carcinoma of the head and neck. However, the mechanism of their antitumor synergism is not fully understood. In the current study, we investigate the mechanism of their synergistic growth-inhibitory effects. The treatment of squamous cell carcinoma of the head and neck cell lines with erlotinib time-dependently increased the expression of cell cycle regulatory proteins p21 and p27 and apoptosis regulatory protein Bim. EGCG alone had very little or no effect on the expression of these proteins among the cell lines. However, simultaneous treatment with EGCG and erlotinib strongly inhibited erlotinib-induced expression of p21 and p27 without affecting the expression of Bim. Moreover, erlotinib increased the expression of p53 protein, the ablation of which by short hairpin RNA strongly inhibited EGCG- and erlotinib-mediated growth inhibition and the expression of p21, p27, and Bim. In addition, combined treatment with erlotinib and EGCG inhibited the protein level of p65 subunit of nuclear factor-B and its transcriptional target Bcl-2, but failed to do so in cells with ablated p53. Taken together, our results, for the first time, suggest that erlotinib treatment activates p53, which plays a critical role in synergistic growth inhibition by erlotinib and EGCG via inhibiting nuclear factor-B signaling pathway. Characterizing the underlying mechanisms of EGCG and erlotinib synergism will provide an important rationale for chemoprevention or treatment trials using this combination.

Key Words: Chemoprevention • EGFR-TKI • molecular targets • p53

This article has been cited by other articles:

				A. S. Tsao, D. Liu, J. Martin, X.-m. Tang, J. J. Lee, A. K. El-Naggar, I. Wistuba, K. S. Culotta, L. Mao, A. Gillenwater, et al. Phase II Randomized, Placebo-Controlled Trial of Green Tea Extract in Patients with High-Risk Oral Premalignant Lesions Cancer Prevention Research, November 1, 2009; 2(11): 931 - 941. [Abstract] [Full Text] [PDF]

				A. M. Bode and Z. Dong Epigallocatechin 3-Gallate and Green Tea Catechins: United They Work, Divided They Fail Cancer Prevention Research, June 1, 2009; 2(6): 514 - 517. [Full Text] [PDF]